Toronto-based NoNO Inc. has become the
first company to show that macaque models have the potential to derisk clinical
testing of new stroke therapies, which typically have gone right from rat or
rabbit models into humans. In February, the company reported that its
neuroprotective peptide NA-1 was effective both in macaque models
of stroke1 and in a Phase II trial to treat ruptured brain
Haas, M.J. SciBX 5(12);
Published online March 22, 2012
1. Cook, D.J. et al. Nature; published online Feb. 29, 2012;
Contact: Michael Tymianski, Toronto Western Research
Institute, Toronto, Ontario, Canada
2. Fisher, M. et al. Stroke 40, 2244-2250
3. Aarts, M. et al. Science 298, 846-850 (2002)
4. Bråtane, B.T. et al. Stroke 42, 3265-3270
AND INSTITUTIONS MENTIONED
(Xetra:BAYN), Leverkusen, Germany
Beth Israel Deaconess Medical Center, Boston, Mass.
Boehringer Ingelheim GmbH, Ingelheim, Germany
Genentech Inc., South San Francisco, Calif.
Harvard Medical School, Boston, Mass.
H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark
Toronto, Ontario, Canada
(Xetra:PA8), Aachen, Germany
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Thrombolytic Science International LLC, Cambridge, Mass.
Toronto Western Hospital, Toronto, Ontario, Canada
Toronto Western Research Institute, Toronto, Ontario, Canada
University of Toronto, Toronto, Ontario, Canada
Warren Pharmaceuticals Inc., Westchester, N.Y.